PeptiCRAd, a Platform for Neoantigen Vaccine Delivery in Cancer

Time: 10:00 am
day: Day One

Details:

• PeptiCRAD is a platform combining oncolytic adenovirus and peptide vaccination in cancer
• Peptide antigens are non-covalently/electrostatically attached to the virus surface without compromising OV activity and generate potent cytotoxic CD8+ T cell responses to tumors
• PeptiCRAd offers an ideal platform to test novel neoantigens preclinically and in the clinic